Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by OKYO Pharma LTD < Previous 1 2 Next > OKYO Pharma Limited Announces Withdrawal of Public Offering September 14, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Public Offering of Ordinary Shares September 13, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease September 08, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”) August 30, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule August 29, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023 August 15, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited Announces Withdrawal of Public Offering July 31, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Proposed Public Offering of Ordinary Shares July 28, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited Receives Nasdaq Deficiency Notice July 28, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center July 28, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer July 27, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease June 06, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform May 11, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023 May 03, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease May 02, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease April 25, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO Notice of General Meeting and Publication of Circular April 05, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO Notice of Intention to Delist From The London Stock Exchange April 04, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Today Announces Director Acquires Shares March 30, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Today Announces Director Acquires Shares March 29, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces PDMR Dealing March 24, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website March 16, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management March 14, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited Prices $5.3 Million Offering of ADSs March 13, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease February 28, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board February 23, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. February 21, 2023 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022 December 30, 2022 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease December 22, 2022 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO OKYO to Participate at Biotech Showcase December 21, 2022 From OKYO Pharma LTD Via GlobeNewswire Tickers OKYO < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
